Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fabrizio Montecucco, Alessandra Quercioli, Franco Dallegri, Giorgio Luciano Viviani & François Mach. (2010) New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Review of Cardiovascular Therapy 8:10, pages 1457-1467.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Dimitri P Mikhailidis, Efstathios D Pagourelias, Anna I Kakafika, Athanasios Skaperdas, Apostolos Hatzitolios & Asterios Karagiannis. (2007) Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opinion on Pharmacotherapy 8:14, pages 2267-2277.
Read now
Read now
James M Backes, Cheryl A Gibson & Patricia A Howard. (2005) Optimal Lipid Modification: The Rationale for Combination Therapy. Vascular Health and Risk Management 1:4, pages 317-331.
Read now
Read now
Harold E Bays. (2004) Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Review of Cardiovascular Therapy 2:4, pages 485-501.
Read now
Read now
Articles from other publishers (18)
Dustin L. Cooper, Derek E. Murrell, David S. Roane & Sam Harirforoosh. (2015) Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery. International Journal of Pharmaceutics 490:1-2, pages 55-64.
Crossref
Crossref
Daniel AcostaJr.Jr.. 2001. Patty's Toxicology. Patty's Toxicology
583
602
.
Carol M. Mason & Amy L. Doneen. (2012) Niacin—A Critical Component to the Management of Atherosclerosis. Journal of Cardiovascular Nursing 27:4, pages 303-316.
Crossref
Crossref
Alan Shenkin & Norman B. Roberts. 2012. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics
895
983
.
Terry A. Jacobson. (2010) A “Hot” Topic in Dyslipidemia Management—“How to Beat a Flush”: Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention. Mayo Clinic Proceedings 85:4, pages 365-379.
Crossref
Crossref
György Paragh & Péter Fülöp. (2009) Impact of lipid lowering therapy on liver function. Orvosi Hetilap 150:26, pages 1205-1212.
Crossref
Crossref
Rajesh Peter & Alan Rees. (2009) Diabetes and cardiovascular disease: new perspectives. Current Opinion in Lipidology 20:2, pages 145-146.
Crossref
Crossref
Subharekha Raghavan, G. Scott Tria, Hong C. Shen, Fa-Xiang Ding, Andrew K. Taggart, Ning Ren, Larrisa C. Wilsie, Mihajlo L. Krsmanovic, Tom G. Holt, Michael S. Wolff, M. Gerard Waters, Milton L. Hammond, James R. Tata & Steven L. Colletti. (2008) Tetrahydro anthranilic acid as a surrogate for anthranilic acid: Application to the discovery of potent niacin receptor agonists. Bioorganic & Medicinal Chemistry Letters 18:11, pages 3163-3167.
Crossref
Crossref
John A. Wagner. (2008) Strategic Approach to Fit-for-Purpose Biomarkers in Drug Development. Annual Review of Pharmacology and Toxicology 48:1, pages 631-651.
Crossref
Crossref
Sidharth S. Bhardwaj & Naga Chalasani. (2007) Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity. Clinics in Liver Disease 11:3, pages 597-613.
Crossref
Crossref
E Lai, I De Lepeleire, T M Crumley, F Liu, L A Wenning, N Michiels, E Vets, G O'Neill, J A Wagner & M Berkwits. (2007) Suppression of Niacin-induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1. Clinical Pharmacology & Therapeutics 81:6, pages 849-857.
Crossref
Crossref
Steven G. Chrysant & Mohammad Ibrahim. (2006) Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. The Journal of Clinical Hypertension 8:7, pages 493-501.
Crossref
Crossref
FD Richard Hobbs. (2006) Reducing cardiovascular risk in diabetes: Beyond glycemic and blood pressure control. International Journal of Cardiology 110:2, pages 137-145.
Crossref
Crossref
Kailash Prasad. (2006) C‐Reactive Protein (CRP)‐Lowering Agents. Cardiovascular Drug Reviews 24:1, pages 33-50.
Crossref
Crossref
Zoltán Benyó, Andreas Gille, Jukka Kero, Marion Csiky, Marie Catherine Suchánková, Rolf M. Nüsing, Alexandra Moers, Klaus Pfeffer & Stefan Offermanns. (2005) GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing. Journal of Clinical Investigation 115:12, pages 3634-3640.
Crossref
Crossref
Edward Heath. 2005. Sports Nutrition. Sports Nutrition
69
90
.
Florian Kronenberg, Arno Lingenhel, Karl Lhotta, Barbara Rantner, Martina F. Kronenberg, Paul König, Joachim Thiery, Michael Koch, Arnold Von Eckardstein & Hans Dieplinger. (2004) Lipoprotein(a)- and low-density lipoprotein–derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?. Kidney International 66:1, pages 348-354.
Crossref
Crossref
Timothy T. Jiang & Daniel AcostaJr.Jr.. 2001. Patty's Toxicology. Patty's Toxicology.